Smartphone app aims to catch rheumatoid arthritis before it takes hold

NCT ID NCT07825233

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers are testing whether a smartphone app called DETECTRA can help doctors diagnose rheumatoid arthritis earlier in adults who have joint symptoms and a positive ACPA blood test. Participants are randomly assigned to receive standard care alone or standard care plus the app. Those using the app answer symptom questions and take hand photos every two weeks, which doctors review remotely. The trial measures how long it takes to reach a diagnosis and how well symptoms are controlled over 24 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
DETECTRA remote monitoring app
What this could lead to
If it works, remote monitoring could help doctors spot rheumatoid arthritis sooner, when treatment may work better.
What could go wrong
The app may not speed up diagnosis compared with standard care. Some participants may find the every-two-week tasks burdensome, and the study is limited to 142 people.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 142 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jul 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Must provide and sign the study's Informed Consent prior to any study-related procedures * Able to understand and interact with the study team * Agree to comply in good faith with all conditions of the recordings, and to attend all required study procedures. * Arthralgia (including hand joints PIP and or MCP) * Joint symptoms (arthralgia or stiffness) of recent onset (symptoms \<1 year) * Known positive ACPA-titer with written proof * Aged 18 years-old or more Exclusion Criteria: * Deformation of the hands or patients who have undergone joint arthrodesis or arthroplasty * Known microcrystal disease (e.g. gout, calcium pyrophosphate deposition) if hands are affected or pre-existing immune-mediated rheumatic diseases such as systemic lupus erythematosus or Sjögren's disease * Fulfilling the ACR/EULAR 2010 classification criteria for diagnosis of RA (≥ 6 points) * Known or suspected clinical synovitis by physician in \> 3 small joints (with or without involvement of large joints) * Any previous b, ts, and csDMARDs use * Lymphoedema in arms or hands following an axillary lymph node dissection * Inability to provide written informed consent * Severe cognitive impairment, severe psychiatric conditions or other inability to follow the procedures of the study * Immunosuppressive therapy for other autoimmune conditions \<2 years ago * Any Immunosuppressive therapy for other autoimmune conditions with B-cell depletion * Haematological or oncological treatments involving induction and / or maintenance chemotherapy within the last 5 years are not permitted * Participation in another investigation with an investigational drug or another MD within the 30 days preceding the trial or currently participating or planning to participate in an interventional trial * No regular (at least every 2 weeks) access to a smartphone * Adults who lack capacity to consent, known pregnant and breastfeeding women * Subjects for whom routine examination of the musculoskeletal system is not possible, or whose hands cannot be imaged (e.g., bandages that cannot be removed for hand picture taking, or injuries affecting the PIP joints both persisting for \> 49 days) * Enrolment of the PI, his/her family members, employees and other dependent persons

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rheumatoid arthritis (RA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier Unversitaire Vaudois

    Lausanne, 1011, Switzerland

  • Charite Universitätsmedizin Berlin

    Berlin, Germany

  • Copenhagen Center for Arthritis Research (COPECARE), Rigshospitalet

    Copenhagen, Denmark

  • Medical University Vienna

    Vienna, Austria

  • Ruhr University Bochum

    Bochum, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.